ozanezumab (GSK 1223249) / GSK - LARVOL DELTA

Protein-driven mechanism of multiorgan damage in COVID-19. (PubMed, Med Drug Discov) - "After removal of drugs having undesirable drug-drug interactions we select 7 drugs and one natural product: apabetalone, romidepsin, silmitasertib, ozanezumab, procaine, azacitidine, amlexanox, volociximab, and ellagic acid, whose combinations can palliate the organs and systems found to be damaged by COVID-19. We found that at least 4 drugs are needed to treat all the multiorgan damages, for instance: the combination of romidepsin, silmitasertib, apabetalone and azacitidine."

Journal • Cardiovascular • Dermatology • Gastrointestinal Disorder • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - P1; N=3; Terminated; Sponsor: GlaxoSmithKline; Trial primary completion date: Nov 2012 ->Jan 2012

Trial primary completion date • Biosimilar • Immunology • Multiple Sclerosis